At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 400 enrolled
Drug / intervention
Ivermectin Tablets +1 moredrug
Likely dose
Ivermectin Tablets 200 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre Randomised, Double-Blind, Placebo-controlled, Study to Evaluate the efficAcy and Safety of Oral IVErmectin Tablets in the Prevention of COVID-19
In Brief
A Phase 2 clinical trial evaluating Ivermectin Tablets and Matching placebo tablets for COVID-19. Completed, enrolled 400 participants across 1 site.
Detailed Summary
A multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy and safety of oral ivermectin tablets versus placebo for COVID-19 prophylaxis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesBulgaria
CollaboratorsViolaine Desort-Hénin, DVM
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartMar 2022
First PostedMar 2022
Primary CompletionSep 2022
Study CompletionOct 2022
TodayJul 2026
First PostedMar 31, 2022
Enrollment StartMar 25, 2022
Primary CompletionSep 15, 2022
Study CompletionOct 13, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.3 years ago
Interventions
Ivermectin Tabletsdrug
Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.
Matching placebo tabletsdrug
Daily placebo tablets intake for 28 days